Melatonin loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles reduce inflammation, inhibit apoptosis and protect rat's liver from the hazardous effects of CCL4.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Melatonin*/pharmacology ; Nanoparticles*/chemistry; Animals ; Male ; Rats ; Anti-Inflammatory Agents/pharmacology ; Antioxidants/pharmacology ; Apoptosis ; Drug Carriers/chemistry ; Inflammation ; Liver ; Polyethylene Glycols/chemistry ; Polylactic Acid-Polyglycolic Acid Copolymer ; Rats, Sprague-Dawley

Liver is an important organ that carries out major important functions including the detoxification of harmful chemicals. Numerous studies have lately focused on the impact of various substances, such as chemical pollutants and pharmaceutical drugs, on the liver. Melatonin (Mel) has been reported for the protection against liver injury. In order to enhance Mel therapeutic benefits and prevent any potential negative effects, Mel has to be delivered to the injured liver. Therefore, the goal of the current investigation was to create Mel-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (Mel-PLGA NPs) to alleviate carbon tetrachloride (CCL4)-induced liver damage in male Sprague Dawley rats. The prepared Mel-PLGA NPs were physically characterized to determine its size and charge. Moreover, Mel-PLGA NPs were examined, in vitro, to determine its antioxidant, anticoagulant, anti-inflammatory and cytotoxicity effects before being used in vivo. The effect of NPs on liver injury was evaluated through biochemical, immunological, histopathological examination and flow cytometry technique. Mel-PLGA NPs were smooth and spherical with no signs of aggregation and have in vitro antioxidant, anti-inflammatory and anticoagulant effects. NPs varied in size from 87 to 96 nm in transmission electron microscope images, while their hydrodynamic diameter was 41 nm and their zeta potential was -6 mV. Mel-PLGA NPs had encapsulation efficiency (EE%) and drug loading (DL%) of 59.9 and 12.5%, respectively. Treatment with Mel-PLGA NPs ameliorated all histopathological changes, in liver sections, that resulted from CCL4 administration; where, liver sections of treated groups were similar to those of healthy control GI. NPs administration were superior to free Mel and reversed the elevated levels of liver function enzymes, inflammatory cytokines and matrix metalloproteinases to their normal levels. Moreover, liver sections of groups treated with NPs showed negative immunostaining for nuclear factor-κB (NF-κB) and C-reactive protein indicating their anti-inflammatory behavior. Mel-PLGA NPs significantly protected liver from the toxicity of CCL4. The effective dose of NPs was 5 mg/kg indicating a reduction in the required Mel dose and its associated adverse effects.
(© 2023. Springer Nature Limited.)

Lipids Health Dis. 2015 Jul 22;14:75. (PMID: 26199093)
Int J Pharm. 2021 Jun 1;602:120584. (PMID: 33887395)
J Drug Target. 2008 Feb;16(2):108-23. (PMID: 18274932)
Pharmaceutics. 2020 Oct 26;12(11):. (PMID: 33114492)
Molecules. 2015 Oct 16;20(10):18886-906. (PMID: 26501252)
Ulus Cerrahi Derg. 2016 Oct 27;32(4):233-237. (PMID: 28149117)
Crit Rev Toxicol. 2003;33(2):105-36. (PMID: 12708612)
J Pineal Res. 2021 Mar;70(2):e12702. (PMID: 33108677)
J Microencapsul. 2016 Feb;33(1):53-63. (PMID: 26605784)
J Pineal Res. 2017 Apr;62(3):. (PMID: 28152213)
Complement Ther Med. 2019 Feb;42:65-81. (PMID: 30670284)
Toxicol Appl Pharmacol. 2012 Jun 15;261(3):271-9. (PMID: 22521486)
Stem Cell Res Ther. 2022 Dec 21;13(1):528. (PMID: 36544223)
Int J Pharm. 2013 Jan 20;440(2):135-40. (PMID: 23078856)
Carbohydr Polym. 2013 Feb 15;92(2):1908-14. (PMID: 23399236)
Lab Anim. 2015 Apr;49(1 Suppl):4-11. (PMID: 25835733)
Pak J Biol Sci. 2013 Dec 15;16(24):1849-61. (PMID: 24517000)
Eur J Pharmacol. 2009 Aug 15;616(1-3):287-92. (PMID: 19576882)
Int J Mol Sci. 2017 Mar 23;18(4):. (PMID: 28333073)
AMB Express. 2023 Nov 9;13(1):125. (PMID: 37943403)
Biomaterials. 2017 Nov;144:30-41. (PMID: 28820966)
Sci Rep. 2022 Apr 15;12(1):6344. (PMID: 35428860)
Cell Biochem Funct. 2005 May-Jun;23(3):169-74. (PMID: 15386534)
Sci Rep. 2023 Jun 30;13(1):10617. (PMID: 37391460)
J Clin Endocrinol Metab. 1992 Jan;74(1):108-17. (PMID: 1727807)
Daru. 2012 Nov 14;20(1):76. (PMID: 23351977)
J Pineal Res. 2013 Jan;54(1):24-32. (PMID: 22712496)
J Microencapsul. 2014;31(7):700-7. (PMID: 24963961)
Biochimie. 2011 May;93(5):854-66. (PMID: 21354255)
Drug Res (Stuttg). 2017 Jan;67(1):13-19. (PMID: 27684192)
Curr Drug Deliv. 2018;15(4):554-563. (PMID: 28721816)
J Sleep Res. 2003 Sep;12(3):207-12. (PMID: 12941059)
AMB Express. 2023 Nov 20;13(1):129. (PMID: 37985554)
Fibrogenesis Tissue Repair. 2013 Oct 01;6(1):19. (PMID: 24274743)
Physiol Int. 2016 Mar;103(1):94-104. (PMID: 27030631)
Cell Tissue Bank. 2016 Dec;17(4):653-663. (PMID: 27550013)
Cell Biol Toxicol. 2006 Nov;22(6):381-91. (PMID: 16703270)
J Pineal Res. 2016 Oct;61(3):253-78. (PMID: 27500468)
Curr Aging Sci. 2016;9(1):5-13. (PMID: 26632428)
Nutr Metab (Lond). 2013 Feb 03;10(1):20. (PMID: 23374533)
Molecules. 2020 May 08;25(9):. (PMID: 32397080)
Cancer Cell Int. 2022 Jan 29;22(1):43. (PMID: 35093076)
Molecules. 2021 Jun 10;26(12):. (PMID: 34200947)
J Nanobiotechnology. 2023 Oct 13;21(1):373. (PMID: 37828599)
J Pineal Res. 2010 Aug;49(1):78-85. (PMID: 20524971)

0 (Anti-Inflammatory Agents)
0 (Antioxidants)
0 (Drug Carriers)
JL5DK93RCL (Melatonin)
3WJQ0SDW1A (Polyethylene Glycols)
1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)

Date Created: 20230930 Date Completed: 20231005 Latest Revision: 20241012

20250114

PMC10543381

10.1038/s41598-023-43546-4

37777583